What is the treatment of Chikungunya virus disease in the sub-acute phase?
The clinical management of Chikungunya varies according to the phase of disease. In the sub-acute phase, the primary aim is to alleviate pain and halt the progression of inflammation.
This protocol applies specifically to the sub-acute phase of Chikungunya virus disease — a distinct stage that requires a targeted management approach focused on ongoing pain control and limiting inflammatory progression.
Treatment approach (partial overview)
Management centres on structured pain control, beginning at an appropriate step of the analgesic ladder — with agent selection guided by the patient's symptom profile. The complete regimen, including specific agents and escalation criteria, is available in the full protocol.
References
- The clinical management of Chikungunya is based on the phase of the disease.
- The main objective of management during this phase is to alleviate pain and stop the progression of inflammation.
- Analgesics: begin with optimizing step 1/2 of the analgesic ladder along with an antineuropathic agent.
- Pain management should begin at step 1 or 2 of the analgesic ladder. Paracetamol ±, opioids, ± anti-neuropathic agents should be prescribed based on the symptoms.
View source ↗